中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
3-环己基-2-(呋喃-3-基)-1H-吲哚-6-羧酸甲酯 | methyl 3-cyclohexyl-2-(3-furyl)-1H-indole-6-carboxylate | 494799-20-1 | C20H21NO3 | 323.392 |
3-环己基-1H-吲哚-6-羧酸甲酯 | methyl 3-cyclohexyl-1H-indole-6-carboxylate | 494799-18-7 | C16H19NO2 | 257.332 |
3-环己烷吲哚-6-甲酸 | 3-cyclohexyl-1H-indole-6-carboxylic acid | 494799-17-6 | C15H17NO2 | 243.305 |
2-溴-3-环己基-1H-吲哚-6-羧酸甲酯 | methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate | 494799-19-8 | C16H18BrNO2 | 336.228 |
3-(1-环己烯-1-基)-1H-吲哚-6-羧酸 | 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid | 494799-16-5 | C15H15NO2 | 241.29 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 3-Cyclohexyl-1-(2-ethoxy-2-oxo-ethyl)-2-(3-furyl)indole-6-carboxylic acid | 1217510-95-6 | C23H25NO5 | 395.455 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-1-[2-(dimethylamino)-2-oxoethyl]-2-(furan-3-yl)indole-6-carboxamide | 1422251-75-9 | C27H35N3O5S | 513.658 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-[2-[2-methoxyethyl(methyl)amino]-2-oxoethyl]indole-6-carboxamide | 1422251-78-2 | C29H39N3O6S | 557.711 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]indole-6-carboxamide | 1026346-81-5 | C30H40N4O5S | 568.737 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-(2-oxo-2-pyrrolidin-1-ylethyl)indole-6-carboxamide | 1422251-77-1 | C29H37N3O5S | 539.696 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-(2-oxo-2-piperidin-1-ylethyl)indole-6-carboxamide | 1422251-76-0 | C30H39N3O5S | 553.723 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-[2-[methyl-(1-methylpiperidin-4-yl)amino]-2-oxoethyl]indole-6-carboxamide | 1422251-80-6 | C32H44N4O5S | 596.791 |
—— | N-tert-butylsulfonyl-3-cyclohexyl-2-(furan-3-yl)-1-[2-[methyl(2-pyridin-2-ylethyl)amino]-2-oxoethyl]indole-6-carboxamide | 1422251-79-3 | C33H40N4O5S | 604.77 |
Acylsulfonamide and acylsulfamide as surrogates for the carboxylic acid function of N-acetamide-indole-6-carboxylic acids were evaluated as allosteric inhibitors of hepatitis C virus (HCV) NS5B polymerase. Several analogs displayed excellent antiviral potency against both 1a and 1b HCV genotypes in cell-based subgenomic replicon assays. Structure–activity relationships (SAR) are discussed in the context of the crystal structure of an inhibitor − NS5B polymerase complex. Absorption, distribution, metabolism, and excretion pharmacokinetic (ADME-PK) properties of this class of inhibitors are also described.